1. Home
  2. CERO
  3. CERO News

Latest CERo Therapeutics Holdings Inc. Common Stock (CERO) News on April 25, 2025

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
CERO

GlobeNewswire

11 hours ago

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
CERO

GlobeNewswire

a day ago

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
CERO

GlobeNewswire

3 days ago

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
CERO

GlobeNewswire

15 days ago

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
CERO

GlobeNewswire

16 days ago

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
CERO

GlobeNewswire

25 days ago

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
CERO

GlobeNewswire

a month ago

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
CERO

GlobeNewswire

a month ago

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
CERO

GlobeNewswire

a month ago

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
CERO

GlobeNewswire

2 months ago

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
CERO

GlobeNewswire

2 months ago

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress
CERO

GlobeNewswire

3 months ago

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CERO

GlobeNewswire

3 months ago

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Cero Therapeutics to effect 1-for-100 reverse stock split
CERO

TipRanks

4 months ago

Cero Therapeutics to effect 1-for-100 reverse stock split

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
CERO

GlobeNewswire

4 months ago

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
CERO

GlobeNewswire

5 months ago

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
CERO

GlobeNewswire

5 months ago

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
CERO

GlobeNewswire

5 months ago

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update
CERO

GlobeNewswire

6 months ago

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
CERO

GlobeNewswire

7 months ago

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
CERO

GlobeNewswire

7 months ago

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
CERO

GlobeNewswire

10 months ago

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
CERO

GlobeNewswire

10 months ago

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Edge Total Intelligence Inc. Updates Status of MCTO
CERO

Newsfile

10 months ago

Edge Total Intelligence Inc. Updates Status of MCTO

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
CERO

CNW Group

10 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
CERO

GlobeNewswire

10 months ago

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
CERO

GlobeNewswire

10 months ago

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
CERO

GlobeNewswire

10 months ago

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
CERO

GlobeNewswire

10 months ago

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
CERO

CNW Group

10 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
CERO

PR Newswire

10 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy
CERO

ACCESSWIRE

a year ago

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
CERO

GlobeNewswire

a year ago

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
CERO

GlobeNewswire

a year ago

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes
CERO

GlobeNewswire

a year ago

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

CERO

Business Wire

a year ago

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

CERO

Business Wire

a year ago

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

Share on Social Networks: